Skip to main content

Thrive Earlier Detection Acquired in $2.15B Deal by Molecular Diagnostics Company Exact Sciences

Baltimore City - based, Thrive Earlier Detection Corp., a JHU cancer diagnostic spinoff, has been acquired by molecular diagnostics company Exact Sciences in a $2.1B deal to further advance development of CancerSEEK, a liquid biopsy test designed to detect multiple types of cancer at early stages. “We believe that this combined team can transform the future of cancer diagnostics,” said Kevin Conroy, CEO of Exact Sciences.

Read More

Subscribe to our mailing list: